291 related articles for article (PubMed ID: 37720344)
1. Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma.
Yoshikawa S; Taniguchi K; Sawamura H; Ikeda Y; Asai T; Tsuji A; Matsuda S
Explor Target Antitumor Ther; 2023; 4(4):556-568. PubMed ID: 37720344
[TBL] [Abstract][Full Text] [Related]
2. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
[No Abstract] [Full Text] [Related]
3. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
Golonka RM; Vijay-Kumar M
Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.
Shen S; Khatiwada S; Behary J; Kim R; Zekry A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565229
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.
Rajapakse J; Khatiwada S; Akon AC; Yu KL; Shen S; Zekry A
Gut Microbes; 2023 Dec; 15(2):2240031. PubMed ID: 37615334
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
7. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
[TBL] [Abstract][Full Text] [Related]
8. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond.
Ohtani N; Kamiya T; Kawada N
Hepatol Commun; 2023 Sep; 7(9):. PubMed ID: 37639702
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.
Costante F; Airola C; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
World J Gastrointest Oncol; 2022 Sep; 14(9):1622-1636. PubMed ID: 36187401
[TBL] [Abstract][Full Text] [Related]
11. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
Dongoran RA; Tu FC; Liu CH
Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
[TBL] [Abstract][Full Text] [Related]
12. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy.
Luo W; Guo S; Zhou Y; Zhao J; Wang M; Sang L; Chang B; Wang B
Front Microbiol; 2022; 13():873160. PubMed ID: 35572649
[TBL] [Abstract][Full Text] [Related]
14. Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review.
Muscolino P; Granata B; Omero F; De Pasquale C; Campana S; Calabrò A; D'Anna F; Drommi F; Pezzino G; Cavaliere R; Ferlazzo G; Silvestris N; Speranza D
Front Oncol; 2023; 13():1247614. PubMed ID: 37692859
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment.
Spanu D; Pretta A; Lai E; Persano M; Donisi C; Mariani S; Dubois M; Migliari M; Saba G; Ziranu P; Pusceddu V; Puzzoni M; Astara G; Scartozzi M
World J Hepatol; 2022 Jul; 14(7):1319-1332. PubMed ID: 36158925
[TBL] [Abstract][Full Text] [Related]
16. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
[TBL] [Abstract][Full Text] [Related]
17. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma.
Nakatsu G
J Gastroenterol Hepatol; 2022 Jan; 37(1):34-38. PubMed ID: 34665475
[TBL] [Abstract][Full Text] [Related]
18. Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma.
Huo R; Chen Y; Li J; Xu Q; Guo J; Xu H; You Y; Zheng C; Chen Y
Curr Oncol; 2023 Feb; 30(2):1818-1830. PubMed ID: 36826102
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.
Yu Q; Wu L; Ji J; Feng J; Dai W; Li J; Wu J; Guo C
J Hepatocell Carcinoma; 2020; 7():271-288. PubMed ID: 33150145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
